Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1

Interventions

Cisplatin 6pembrolizumab 5Nivolumab 5palbociclib 4durvalumab 4Pemetrexed 4atezolizumab 3abemaciclib 3Fulvestrant 3Carboplatin 3Anastrozole 3130-nm albumin-bound paclitaxel 3selpercatinib 2ribociclib 2relatlimab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Radiosurgery 2Paclitaxel 2Letrozole 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Bevacizumab 2AZD9833 2trametinib 1taletrectinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × (225)Ac-PSMA-617 × 1 year × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡